GLP-1 Agonist Litigation Cluster

GLP-1 receptor agonists—Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Trulicity—share a common mechanism of action that slows gastric emptying. Plaintiffs across this cluster allege manufacturers Novo Nordisk and Eli Lilly failed to warn about severe gastroparesis, intestinal pseudo-obstruction, gallbladder disease, and NAION vision loss. Cases are consolidated in MDL 3094 in the Eastern District of Pennsylvania. Bellwether selection is underway and case counts are accelerating as off-label weight-loss prescribing continues to expand the exposed population into the tens of millions.

Member torts

Ozempic / Semaglutide (GLP-1)

MDL 3094 (E.D. Pa.)

Ozempic and other GLP-1 agonists (Wegovy, Mounjaro, Zepbound) are linked to severe gastroparesis, intestinal obstruction, and gallbladder injuries. Plaintiffs allege Novo Nordisk and Eli Lilly failed to warn about delayed gastric emptying despite internal knowledge dating to clinical trials. With tens of millions exposed and the MDL still in early bellwether selection, CPL remains at floor pricing.

Shared risk factors

→ Delayed gastric emptying mechanism shared across the entire drug class
→ Off-label weight-loss prescribing driving rapid population growth
→ FDA label updates in 2023-2026 acknowledging post-market adverse events
→ Tens of millions of U.S. users with limited long-term safety data

GLP-1 Agonist Litigation Cluster

Member torts

Ozempic / Semaglutide (GLP-1)

Shared risk factors

Related topics